Principal Investigator
Alejandra Perez
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230888
Clinical Trial Summary
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647